We studied the graft-versus-leukaemia (GVL) effect in 185 patients with haematological malignancies who underwent unrelated donor haematopoietic stem cell transplantation (HSCT) at Huddinge University Hospital between May 1991 and June 2001. Ninety-five were in first CR/CP and 90 in later stages. Most (86%) of them had a HLA-A, -B and -DR␤1 matched donor. Conditioning usually consisted of total body irradiation and cyclophosphamide, and GVHD prophylaxis of cyclosporine and methotrexate. In the multivariate riskfactor analysis of relapse, we found that disease stage beyond CR1/CP1 (P = 0.02), acute GVHD 0-I (P = 0.02), absence of chronic GVHD (P = 0.02) and ALL (P = 0.02) were independent risk factors for relapse. The incidence of relapse in those with acute GVHD grade II was 18% vs 46% in those with no or grade I (P = 0.04). In patients with or without chronic GVHD, the incidences of relapse were 32% and 48%, respectively (P Ͻ 0.01). The best RFS was seen in patients with chronic GVHD. No difference in RFS was seen in patients with no, mild or moderate acute GVHD. Risk factors for relapse after HSCT with unrelated donors were: acute lymphoblastic leukaemia, disease stage beyond CR1/CP1, absence of chronic GVHD and no, or mild acute GVHD. Overall and relapse-free survival were not improved by the occurrence of acute GVHD. It is well known that patients beyond first complete remission (CR)/chronic phase (CP) have a higher risk of relapse than those in CR1/CP1.
ease stage at transplant, 3 donor type, 4 occurrence of GVHD, 2, 5, 6 conditioning 2 and immune-suppressive regimen. 2, 7, 8 It is well known that patients beyond first complete remission (CR)/chronic phase (CP) have a higher risk of relapse than those in CR1/CP1. 3 T cell depletion of the graft also increases risk of relapse, especially in patients with CML. 7 GVHD has a graft-versus-leukaemia effect (GVL), since patients with mild acute or chronic GVHD have a significantly lower risk of leukaemia relapse after HSCT, than do those without GVHD. 5, 6, 9 Chronic GVHD seems to have the strongest anti-leukaemia effect, 5, 10 at least in recipients of sibling grafts. Risk factors for relapse and GVL effect have been extensively analysed when using sibling donors. However, the GVL effect has not been studied in unrelated donors alone. We evaluated risk factors for relapse in 214 consecutive patients with a malignant disease receiving a HSCT from an unrelated donor at Huddinge University Hospital. We also assessed the GVL effect.
Patients and material

Patients
Two hundred and fourteen patients with a haematological malignancy underwent HSCT from an unrelated donor at Huddinge University Hospital between May 1991 and June 2001. One hundred and eighty-five of these patients relapsed or survived for more than 90 days without relapse and were included in the study. Their diagnoses were AML (44), ALL (56), CML (64) and other malignancies (21) . Ninety-five were in first CR/CP and 90 in later stages. Most (86%) of them had a HLA-A, -B and -DR␤1 matched donor. Nineteen of them had an HLA allele level mismatched donor (7 HLA-B and 12 HLA-DR) and seven a major HLA class I antigen mismatched donor (three HLA-A and four HLA-B). Patient and donor characteristics are shown in Table 1 .
Conditioning
Most patients received cyclophosphamide (CY), 60 mg/kg, on 2 consecutive days, combined with 10 Gy single dose total body irradiation (TBI) ( Table 2 ). Other regimens included busulfan (Bu), 4 mg/kg, on 4 consecutive days combined with CY, or fractionated TBI (4 ϫ 3 Gy) and CY. Nine patients who received a T cell-depleted graft were conditioned with 120 mg of CY and 3 ϫ 2 Gy total lymph-node irradiation, followed by TBI 7.5 Gy. Fourteen 
GVHD prophylaxis
Most patients received cyclosporine (CsA) combined with methotrexate (MTX) ( Table 2) . 15 CsA i.v. was started on day Ϫ1, the dose ranging from 5 to 10 mg/kg/day, with a higher dose given to small children. On the day of SCT, CsA was lowered to 3-7.5 mg/kg/day. On day +1, or as soon as the patient could take CsA orally, 12.5 mg/kg/day, was given in two doses to adults and a higher dose, 12.5-20 mg/kg/day, to children. During the first month, blood CsA levels were kept at approximately 200-300 ng/ml. 15 CsA was discontinued after 6 months if possible. Seven patients with a major HLA-antigen mismatched donor received T cell-depleted grafts. 13 Other immunosuppressive protocols were CsA combined with steroids or mycofenolate mofetil (MMF).
Stem-cell source and supportive care
Forty-six patients received stem cells from peripheral blood (PBSC) and 139 bone marrow. 16 G-CSF was given to 84% of the patients from day 10 after HSCT until ANC Ͼ0.5 ϫ 10 9 /l for 2 consecutive days were reached. 17 
Relapse
Patients were, in general, analysed with morphology of bone marrow (BM) aspirates at 3, 6 and 12 months and then yearly after HSCT. A patient with regenerating peripheral blood (PB) values was considered in clinical remission when less than 5% blast cells among 200 nucleated cells were found in a BM sample, on morphological examination. Morphologic leukaemia relapse was defined as at least 30% blast cells in BM aspirates, or presence of extramedullary leukaemia cells. If more than 5% blast cells, but less than 30%, were detected in BM, this was defined as an early relapse. Molecular relapse was defined as increasing levels of BCR/ABL transcript in PB or BM samples in patients with Philadelphia chromosome positive (Ph+) CML or ALL. With other diagnoses, increasing levels of recipient cells in the leukaemia-affected cell lineage were defined as molecular relapse.
Diagnosis and treatment of GVHD
Both acute and chronic GVHD were diagnosed on the basis of clinical symptoms and/or biopsies (skin, liver, gastrointestinal tract or oral mucosa). 18, 19 Patients were treated for grade I acute GVHD with prednisolone, starting at 2 mg/kg/day, which was tapered after the initial response. 20 In more severe cases, ATG, methylprednisolone, MTX or psoralene and UV light (PUVA) were used. Chronic GVHD was initially treated with CsA and steroids. 21 If no response was seen, some patients were given total lymph node irradiation (TLI), 22 PUVA, 23 and more recently, extracorporeal PUVA. 24 
HLA typing
All patients and donors were retrospectively HLA class I and class II typed by allele level PCR-SSP. 25 
Statistics
The findings were analysed on 15 August 2001. Time to relapse was determined with the life table method using the log-rank (Mantel-Haenzel) test, taking censored data into account, 26 and the Cox regression model was used for uniand multivariate analyses. 27 Time to relapse was used to calculate the cumulative incidence curves, and death was a censored observation, unless relapse had occurred. Only patients having a relapse or surviving at least 90 days without relapse after HSCT, and therefore at risk of relapse, were included in the analysis. Twenty-seven potential risk factors for relapse were studied (Table 3) . Only factors at р10% levels in the univariate analyses were introduced into the stepwise elimination multivariate analyses. This was done to reduce the numbers of competing factors in the multivariate analysis. When performing multiple comparisons there is always a risk of statistical significance by chance. However, only one multivariate analysis for each event (relapse and relapse-free survival) was done. For this reason no Bonferroni correction was undertaken. A female Low risk= CR1/CP1; High risk = later stages; AB0 = blood group antigen; HSCT = haematopoietic stem cell transplantation; ATG = anti-thymocyte globulin; BM = bone marrow; PBSC = peripheral blood stem cells; CMV = cytomegalovirus; G-CSF = granulocyte colony-stimulating factor.
Bone Marrow Transplantation donor was considered as immunized if she had been pregnant or had had a blood transfusion. Patients in CR 1 or CP 1 were considered as early disease, while all others were late disease. An AB0 minor mismatch was a donor who had AB0 antibodies against the patient erythrocytes, while an AB0 major mismatch was a patient who had AB0 antibodies against donor erythrocytes.
Results
GVHD
Twenty-eight (15%) patients had no sign of acute GVHD, while 106 (57%) developed grade I, 39 (21%) grade II, 10 (5%) grade III and 2 (1%) grade IV acute GVHD. Seventyfive patients (40%) developed chronic GVHD, 63 (34%) limited and 12 (6%) extensive. Four patients had 'de novo' chronic GVHD, while the rest had had acute GVHD previously.
Relapse and relapse-free survival
Recurrent disease was diagnosed in 56 of the 185 patients. Eleven of these relapses were detected by molecular methods and 45 morphologically. The cumulative incidence of relapse was 38% at 3 years and 41% at 5 years. The cumulative probability of relapse-free survival was 45% at 3 years, and 41% at 5 years. 
Risk factors for relapse
In the Cox regression univariate analysis, eight factors were significant at the Ͻ5% levels, and one additional factor at the 5-10% level (Table 3 ). In the stepwise elimination multivariate analysis, ALL diagnosis, remission beyond CR1/CP1, absence of chronic GVHD and no, or mild acute GVHD were independent risk factors for relapse in this study (Table 4a ). Among patients with ALL the 5-year incidence of relapse was 57%, compared to 31% (P Ͻ 0.01) in patients with another diagnosis (Figure 1a ). Among patients beyond CR1/CP1, the 5-year incidence of relapse was 50%, compared to 32% (P Ͻ 0.01) in those in CR1/CP1 ( Figure  1b ). Among patients with no, or mild acute GVHD, the incidence of relapse was 46%, compared to 22% (P = 0.04) in those with grades II-IV acute GVHD (Figure 1c) . The incidence of relapse in patients with and without chronic GVHD was 32% and 48%, respectively (P Ͻ 0.01) (Figure 1d ). The incidence of relapse increased with the number of risk factors. If no risk factors were present (n = 11), no relapse occurred. If one risk factor was present (n = 37), the cumulative incidence of relapse was 31%, with two risk factors (n = 73), it was 31%, with three (n = 45) it was 54% and with all four present, it was 81%.
Graft-versus-leukaemia effect
Among patients with acute GVHD II, the cumulative incidence of relapse was 18%, compared to 46% in all others (P = 0.04). We found no difference in the incidence of relapse between patients with grade I and those without acute GVHD (45% vs 48%).
Chronic GVHD was associated with a lower incidence of relapse. The combination of acute GVHD grade II and chronic GVHD was not associated with a lower incidence of relapse than in patients with acute GVHD grade II without chronic GVHD (Figure 2 ). Patients with isolated acute GVHD grade I showed no difference in relapse incidence compared to those without any GVHD, while those with both acute GVHD grade I and chronic GVHD had a lower incidence (Figure 2 ). Among patients with grade III-IV acute GVHD (n = 12) only one relapsed. However, only four of these patients survived more than 6 months, and two for more than 1 year. In this study, moderate-to-severe chronic GVHD was not associated with a stronger antileukaemia effect than was mild disease. 
Survival
The overall 5-year survival in the whole group was 46%. Survival rates among patients with acute GVHD grades 0, I, II and III-IV were 57%, 50%, 49% and 12%, respectively. Patients with chronic GVHD showed a significantly better 5-year survival than did those without, 63% vs 45%, P Ͻ 0.01. Transplant-related mortality (TRM) was 23% for patients with no or mild acute GVHD while it was 43% in patients with grade II acute GVHD (P = 0.02).
Relapse-free survival
In the multivariate risk factor analysis of RFS, we found that chronic GVHD and grades 0-II acute GVHD correlated independently with a better RFS, when adjusted for diagnosis and disease stage (Table 4b ). The 5-year RFS of patients with chronic GVHD was 55%, compared to 39% in those without (P Ͻ 0.01). The 5-year RFS in patients with acute GVHD grades 0-II was 46%, compared to 12% in those with more severe forms (P Ͻ 0.001). We found no differences in RFS rates among those without, with mild or with grade II acute GVHD (49%, 46% and 47%, respectively). The cumulative incidence of RFS in patients with chronic GVHD and acute GVHD 0-II (n = 73) was 57%. RFS rates in patients with various combinations of acute and chronic GVHD are shown in Figure 3 .
DLI treatment
Twenty-five of the patients who relapsed were treated with donor lymphocyte infusion (DLI). Seven (28%) of these entered a new remission after the DLI treatment. Two had only a transient remission, while five are still in CR, with 2-72 months follow-up. Response rates for the different diagnoses are given in Table 5 . In 11 of the DLI-treated patients, relapse was detected with molecular methods, while 14 had a morphologically detected relapse. Among those with a relapse detected by molecular methods, four responded, and all are still alive in remission, while in those with a morphological relapse three responded, and one is still alive in remission. One of eight patients with acute
Bone Marrow Transplantation leukaemia who relapsed within 1 year after HSCT responded to DLI treatment. Among those who had a later relapse, two of four patients responded.
After DLI treatment, 16 patients had no acute GVHD, four grade I, two grade II and three grades III-IV. Chronic GVHD occurred in seven of these patients (Table 5) . Among those still alive and in remission (n = 5) after DLI treatment, two did not develop acute GVHD, two had mild and one moderate disease, while chronic GVHD occurred in four. Of those who had only a short remission, one had acute GVHD and one chronic GVHD. On logistic regression analysis, chronic GVHD (OR 20.0, 95% CI 1.96-204, P Ͻ 0.01) was strongly correlated with induction of a new remission after DLI, while acute GVHD was not.
Discussion
Various factors affecting the incidence of recurrence of leukaemia after HSCT have been reported. 2 However, previous studies have mainly been undertaken in patients receiving related donor transplants. These have shown that acute GVHD of any grade, and chronic GVHD, play an important role in lowering the incidence of leukaemia relapse. 2, 5, 6, 9 The findings of these studies together with the observation that donor lymphocyte infusions can cure patients with relapse [28] [29] [30] [31] have been interpreted as indicating that GVHD is associated with a graft-versus-leukaemia (GVL) effect. The present study is the first to evaluate risk factors for relapse and the GVL effect solely in patients receiving transplants from unrelated donors.
We found that patients with ALL had a significantly higher incidence of relapse than those having other diagnoses. Many of them (61%) were beyond first remission. This was expected because results with chemotherapy in children with ALL are very good. This means that only the most severe cases are transplanted, leading, not surprisingly to a high relapse rate. However, most patients with AML (64%) were also beyond first CR. Furthermore, an ALL diagnosis was a risk factor for relapse independent of dis- Table 5 Response rates after donor-lymphocyte infusion (DLI) treatment of relapse after haematopoietic stem cell transplantation (HSCT) ease stage on multivariate analysis. Many of the patients with ALL considered to be in CR have recently been shown to harbour high levels of minimal residual disease (MRD), which was associated with an increased relapse rate.
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These results may indicate that ALL is less responsive to a GVL effect than are other haematological malignancies.
All patients with haematological malignancies given a HSCT from an unrelated donor could be considered at high risk for relapse. Patients in first CR have high-risk criteria, such as chromosomal aberrations, high leukocyte counts at diagnosis or difficulty in achieving remission. 33 In this study, however, we did not evaluate these criteria.
Many studies have shown that patients beyond first CR/CP are at high risk of relapse after HSCT, 3 which was confirmed by our study. Here, this effect was most obvious in patients with AML, where none of those in CR1 had a relapse (n = 16) vs 56% of those with later disease stages (n = 28). Among patients with ALL, the corresponding figures were 41% vs 64%.
It is also well known that relapse rates are lower in patients with GVHD. 2, 5, 6, 9 This GVL effect is thought to be strongest in chronic GVHD, 5, 10 while acute GVHD of any grade has a weaker anti-leukaemia effect. 5, 10, 34 We found no difference in relapse rates between patients without acute GVHD and those with mild disease. This may be explained by a suggested GVL effect even in the absence of GVHD. 35 In the multivariate risk factor analysis in our study, no, or mild acute GVHD was a risk factor for relapse (P = 0.02), but absence of acute GVHD compared to any grade was not. Chronic GVHD was also correlated with a lower incidence of relapse (P = 0.02). In the present study, acute GVHD grade II had a strong GVL effect. We failed to find a stronger GVL effect in patients with grades III-IV acute GVHD. The reason for this is that very few (2/12) of these patients survived more than 1 year after HSCT. The lowest relapse rate was found in patients with acute GVHD grade II and chronic GVHD, but this was not significantly better than among patients with acute GVHD grade II without chronic GVHD (Figure 2 ). Since patients with haematological malignancies given a HSCT from an unrelated donor could be considered as high risk, they probably need a stronger GVL effect to eradicate their disease. This is probably why we failed to find a GVL effect from mild acute GVHD in these patients. In contrast, among patients with leukaemia given marrow from an HLA-identical sibling, those with acute GVHD grade I had the best RFS. 36 For such a transplant, patients with lower risk of relapse are also considered and therefore even mild GVHD had a GVL effect.
In accordance with the risk factor analysis for relapse, we found the best RFS rates in patients with chronic GVHD and acute GVHD grades 0-II. However, long-term survival was not different from those without GVHD (Figure 3) . The lower relapse incidence in patients with acute GVHD grades II-IV was diminished by a higher transplant-related mortality (TRM) among these patients. As a result we did not find any difference in RFS rates in patients without, or with mild or moderate acute GVHD (49%, 46% and 47%), while grades III-IV gave a very poor outcome (Figure 3 ). This indicates that GVHD is something to be avoided.
Response rates to DLI have been shown to depend on time of relapse, disease, induction of GVHD and grade of disease at treatment. 37 The best results have been found in patients with CML, while those with ALL have very low response rates 29, 38 suggesting that the GVL effect is weaker in this group. However, in the present study three of nine patients with ALL responded to DLI treatment, which was comparable to the response rate in patients with CML (4/11) ( Table 5 ). Our data suggest that patients with ALL relapsing after HSCT may be salvaged by cell therapy. This is in line with observations by Slavin et al. 39 but in contrast to other reports. 29, 38 It has previously been shown that response rates in patients with acute leukaemia who relapse early (within 1 year after HSCT) are far worse than if the relapse occurs later. 37 This was confirmed in this study. However, the numbers are small and many more patients are needed for a conclusion on this point. DLI treatment induced remission in seven of 25 (28%) treated patients. Among those, we found a correlation between chronic GVHD and a new remission (P Ͻ 0.01). Five of the seven patients with chronic GVHD entered a new remission (Table 5) . Early detection and treatment of recurrent disease after HSCT has been shown to positively affect results. 37 With sensitive molecular methods recurrent disease may be detected several weeks or months prior to morphological relapse. 40, 41 In the present study, four of the five patients with a long-lasting remission received their DLI treatment after a relapse detected by molecular means. This may indicate that response rates after DLI treatment in acute leukaemia may improve with early detection of recurrent disease. We conclude that using unrelated donors, the strongest anti-leukaemia effect was seen in acute GVHD grade II. It may be risky to attempt and induce grade II acute GVHD in recipients of unrelated grafts to have the strongest possible GVL effect. This may not be necessary because overall and RFS were as good in patients with no, or mild GVHD only (Figure 3) . After DLI treatment from unrelated donors, chronic GVHD was correlated with a high rate of remission induction.
